Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
RESEARCH TOOLSreports
LQDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.26 - $16.99
Previous CloseN/A
Volume97.81K
Average Volume (3M)839.34K
Market Cap
$1.22B
Enterprise Value$581.49M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 13, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding84,636,620
10 Day Avg. Volume1,047,283
30 Day Avg. Volume839,340
Standard Deviation0.20
R-Squared0.00338
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)77.86
Price to Cash Flow (P/CF)-12.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit39.83
Enterprise Value/Ebitda-5.43
Forecast
1Y Price Target
$25.86Price Target Upside70.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Liquidia Technologies News
PremiumCompany Announcements
Liquidia Corporation’s Q3 2024 Financial Highlights
---
Bulls Say, Bears Say
Bulls Say
Clinical DataNew clinical data highlights Yutrepia's emerging superior tolerability profile in PH-ILD patients.
FDA ApprovalA clear line of sight for FDA approval of Yutrepia in both PAH and PH-ILD.
Market OpportunityYutrepia will launch into a PAH/PH-ILD opportunity that will have grown into a $2B market by mid-2025.
Bears Say
FDA DelayDisappointed with a -2% performance mostly due to the mid-Aug setback when FDA delayed approval by retroactively granting Tyvaso DPI a 3-yr exclusivity dating to 2022.
Patent LitigationOn the 3Q call, LQDA would not firmly commit to immediately launching Yutrepia in May for the ILD indication, which would be at-risk to ongoing ‘327 patent litigation.
Regulatory ChallengesLQDA is challenging FDA's decision to delay final approval until after expiration of Tyvaso DPI exclusivity.
---
Ownership Overview
36.14% Insiders
5.55% Mutual Funds
0.02% Other Institutional Investors
49.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $8.26 and its highest was $16.99 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $1.22B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Mar 13, 2025 which is in 36 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Nov 13, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.374 by $0.074.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is -0.38.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 84,636,620 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.374. Following the earnings report the stock price went down -3.387%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Among the largest hedge funds holding Liquidia Technologies Inc’s share is Farallon Capital Management, L.L.C.. It holds Liquidia Technologies Inc’s shares valued at 33M.
---
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.86 (70.69% Upside)
$25.86 (70.69% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.07%
12-Months-Change
Fundamentals
Return on Equity
-108.10%
Trailing 12-Months
Asset Growth
126.52%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
---
LQDA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call expressed optimism about Liquidia's strategic and clinical progress, particularly in advancing YUTREPIA towards approval and expanding partnerships. However, ongoing legal challenges and increased expenses pose significant hurdles.Read More>---
LQDA Stock 12 Month Forecast
Average Price Target
$25.86
▲(70.69% Upside)
Technical Analysis
Best Analysts Covering LQDA
1 Year
1 Year Success Rate
11/11 ratings generated profit
1 Year Average Return
+47.63%
reiterated a buy rating 7 days ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +47.63% per trade.
---